Recruiting
Phase 3

VLDRT vs. Standard Dose

Sponsor:

Memorial Sloan Kettering Cancer Center

Code:

NCT07029217

Conditions

Follicular Lymphoma

Marginal Zone Lymphoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Radiation (Standard)

Radiation (Very low dose)

Study Details

Brief summary:

The researchers are doing this study to find out whether a very low dose of radiation therapy (VLDRT) is an effective treatment for people with follicular lymphoma (FL) or marginal zone lymphoma (MZL) and works as well as the standard dose of radiation therapy. The researchers will see if VLDRT works against cancer in the area that is currently affected by cancer and if the therapy prevents new spots of lymphoma from developing. The researchers will also compare VLDRT with the standard dose of radiation therapy to see if VLDRT causes fewer side effects.

Radiation therapy uses beams of intense energy to kill cancer cells. Standard doses of radiation therapy can cause short- and long-term side effects. Researchers think VLDRT may be as effective as standard doses, and, because VLDRT uses less radiation, researchers think VLDRT may cause fewer side effects than standard doses.

Conditions

Follicular Lymphoma

Marginal Zone Lymphoma

Study ID

NCT07029217

Start date

Jun 9, 2025

Status verified date

Feb, 2026

Completion date

Jun, 2028

Anticipated

Primary completion date

Jun, 2028

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria: (Arms 1\&2)

  • Patients must be diagnosed with a follicular lymphoma or marginal zone lymphoma. Of note, there are now two widely-utilized pathology classification criteria used for mature B-cell lymphomas, the World Health Organization (WHO) 5th Edition Classification of Lymphoid Neoplasms and the International Consensus Classification (ICC) of Mature Lymphoid Neoplasms. Either criteria is acceptable and for the purposes of this protocol, the following diagnoses are included:

  • Follicular lymphoma

  • WHO 5th Edition

  • Classic follicular lymphoma (cFL)
  • Follicular lymphoma with uncommon features (uFL)
  • Pediatric type follicular lymphoma
  • Duodenal type follicular lymphoma
  • ICC

  • Follicular lymphoma, grades 1-2 or 3A
  • BCL2 rearrangement negative, CD23 positive follicle center lymphoma
  • Pediatric type follicular lymphoma
  • Duodenal type follicular lymphoma
  • Marginal zone lymphoma

  • WHO 5th Edition and ICC

  • Nodal marginal zone lymphoma
  • Pediatric nodal marginal zone lymphoma
  • Extranodal marginal zone lymphoma of mucosa associated lymphoid tissue (MALT)
  • Patients must have stage I or II disease (with stage I defined as involvement of one nodal region and stage II as two or more nodal regions involved on the same side of the diaphragm)
  • Patients should be newly diagnosed or previously observed with no prior lymphoma-directed therapy
  • If the patient is referred for localized gastric MALT lymphoma, there should be documented negative H. Pylori testing within 6 months prior to proposed radiotherapy
  • Age at the time of enrollment of ≥18 years
  • Patients must be able to start radiation within 2 months from time of randomization

Exclusion Criteria:

  • Prior radiation to site(s) needing treatment
  • Follicular lymphoma, grade 3B (ICC) or Follicular large B cell lymphoma (FLBL by WHO 5th edition criteria)
  • Patients planned to receive concurrent systemic therapy (including oral steroids) for their lymphoma
  • Patient has cutaneous only iNHL defined as primary cutaneous B-cell lymphoma, primary cutaneous follicle center lymphoma, cutaneous marginal zone lymphoma or unspecified indolent lymphoma of the skin
  • Gross total resection of all disease
  • Tumor size measuring ≥5 cm in maximum diameter on any modality diagnostic imaging
  • Patients with any concurrent medical or psychiatric condition or disease which, in the investigator's judgment, would make them inappropriate candidates for entry into this study

Study Design

Enrollment

375 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

active comparator: Very low dose of Radiation

Patients will receive a total of 4 Gy in 1-2 consecutive daily fractions comprehensively to all initially involved sites of disease. At 12 weeks (+/- 4 weeks) post VLDRT, the patient will undergo repeat imaging and clinical evaluation.

experimental: Standard dose of Radiation

Patients will receive a total of 24 Gy in 12 fractions comprehensively to all initially involved sites of disease over 12 consecutive business days. At 12 weeks (+/- 4 weeks) post VLDRT, the patient will undergo repeat imaging and clinical evaluation.

Interventions

Radiation (Standard)

24 Gy in 12 fractions

Radiation (Very low dose)

4 Gy in 1-2 consecutive daily fractions

Primary outcome measure

  • progression-free survival [ Time Frame: 2 years ]

Central Contacts and Locations

Central contacts

Brandon Imber, MD

631-212-6346imberb@mskcc.org

Joachim Yahalom, MD

646-608-2639

Locations

Memorial Sloan Kettering Basking Ridge (All Protocol Activities)

Recruiting

Basking Ridge, New Jersey, United States, 07920

Contacts

Brandon Imber, MD

631-212-6346

Memorial Sloan Kettering Monmouth (All Protocol Activities)

Recruiting

Middletown, New Jersey, United States, 07748

Contacts

Brandon Imber, MD

631-212-6346

Memorial Sloan Kettering Bergen (All Protocol Activities)

Recruiting

Montvale, New Jersey, United States, 07645

Contacts

Brandon Imber, MD

631-212-6346

Memorial Sloan Kettering Suffolk - Commack (All Protocol Activities)

Recruiting

Commack, New York, United States, 11725

Contacts

Brandon Imber, MD

631-212-6346

Memorial Sloan Kettering Westchester (All Protocol Activities)

Recruiting

Harrison, New York, United States, 10604

Contacts

Brandon Imber, MD

631-212-6346

Memorial Sloan Kettering Cancer Center (All Protocol Activities)

Recruiting

New York, New York, United States, 10065

Contacts

Brandon Imber, MD

631-212-6346

Memorial Sloan Kettering Nassau (All Protocol Activities)

Recruiting

Uniondale, New York, United States, 11553

Contacts

Brandon Imber, MD

631-212-6346

More Information

Sponsor

Memorial Sloan Kettering Cancer Center

Last update posted

Feb 17, 2026

Last verified

Feb, 2026

Keywords

  • Stage I-II
  • Radiotherapy
  • 25-089

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-08. This information was provided to ClinicalTrials.gov by Memorial Sloan Kettering Cancer Center on 2026-02-17.